- small-molecule
allosteric and
cardiac myosin inhibitor. It was
developed by
MyoKardia, a
subsidiary of
Bristol Myers Squibb. In
clinical studies, mavacamten...
- inhibitors. In October, BMS
announced it
would acquire cardiology company MyoKardia for $13.1
billion ($225 per share)
gaining control of mavacamten, a cardiovascular...
- Hospital".
Retrieved 5 May 2019. "
MyoKardia". www.
myokardia.com.
Retrieved 5 May 2019. "
MyoKardia". www.
myokardia.com.
Retrieved 5 May 2019. "Christine...
- as the
chief operating officer and
chief development officer for
MyoKardia.
Myokardia was
acquired by
Bristol Myers Squibb for $13.1
billion in November...
- Karyopharm, Keryx, Kura Oncology,
Keros Therapeutics, Maze Therapeutics,
MyoKardia, MyOme, Natera, Nurix,
Olema Oncology, Orexigen,
Pacific Biosciences,...
- Seidman".
Harvard Magazine. 1
November 2002.
Retrieved 5 May 2019. "
MyoKardia". www.
myokardia.com.
Retrieved 5 May 2019. "Jonathan Seidman". www.nasonline.org...
- Leader.
Archived from the
original on 2020-06-26.
Retrieved 2020-06-24. "
Myokardia posts positive phase III for mavacamten". www.bioworld.com. Retrieved...
-
Alpelisib Novartis PIK3CA-related
overgrowth spectrum conditions Mavacamten Myokardia Inc
class II-III
obstructive hypertrophic cardiomyopathy Trastuzumab deruxtecan...
-
Sabry from UCSF and
Larry Goldstein from UCSD.
Spudich also co-founded
MyoKardia in 2012
which was
acquired by
Bristol Myers Squibb in 2020 for $13.1 billion...
